Congestive heart failure is a chronic and growing situation that affects the pumping capacity of heart muscles. In this situation, the heart is unable to pump the blood and circulate it into different parts of the body. Congestive heart failure develops when arteries are unable to pump a sufficient amount of blood to different parts of the body. Ultimately, blood and other fluids get accumulated inside the lungs, liver, abdomen, and lower body part. There are two types of congestive heart failure like systolic heart failure and diastolic heart failure. Congestive heart failure drugs are helpful in such a situation and help the body to get rid of excess fluids and sodium through urination. The drugs help to relieve the heart’s workload. It helps in decreasing the buildup of fluid in the lungs and other parts of the body. According to WHO, around 6.5 million people are diagnosed with congestive heart failure every year and around 2% of the global population are hospitalized due to congestive heart failure. Congestive heart failure can also be treated by a number of devices that maintain heart rhythms, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). The Congestive Heart Failure Drugs Market valued USD 22.9 billion in 2020 and it is expected to reach USD 49.5 billion by 2030 with the CAGR of 8% during the forecast period.

Market Segmentation:

Global congestive heart failure drugs market is segmented by drug class as beta-blockers, ACE inhibitors, angiotensin receptor blockers, diuretics, inotropic agents, aldosterone antagonist, calcium channel blockers, and others. By route of administration the market can be divided into oral and intravenous. By end-user, the market can be bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the congestive heart failure drugs market is divided into North America, APAC, Europe, and the RoW. 

Market Dynamics and Factors:

Rising predominance of cardiovascular diseases across regions is one of the major factors anticipated to drive the revenue growth of congestive heart failure drugs across the globe. Constantly changing lifestyle habits which includes unhealthy dietary habits, smoking, obesity, excessive alcohol consumption, and lack of physical activity, which make individuals more susceptible to arrhythmia and heart failure. The presence of congestive heart failure treatment devices like (Cardiac Resynchronization Therapy (CRT), Left ventricular assist device (LVAD), Implantable cardioverter defibrillator (ICD), and others are the major restraint for the congestive heart failure drugs market.  The arrival of innovative drugs such as EOM is projected to change the market dynamics. Excessive use of drugs has side effects like vomiting, abnormal heart rhythm, and blurred or colored vision which may cause palpitation or fainting are the reasons that will slow down the congestive heart failure drugs market.

Geographic Analysis:

The heart failure market is set to rise from around USD 3.2 billion in 2015 to USD 11.8 billion by 2025, representing a CAGR of 13.7%, according to research study. Novartis and AstraZeneca hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain as market leaders during the forecast period. Countries such as China, India, and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as a large global population and a rising aging population are leading to the high growth of the healthcare sector in developing countries.

Competitive Scenario:

The major players in the global congestive heart failure drug market are AstraZeneca plc. (UK), Bristol-Myers Squibb Co. (U.S), GlaxoSmithKline plc. (GSK) (UK), Merck & Co. Inc. (U.S), Mylan Inc. (U.S), Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), and Valeant Pharmaceuticals International Inc. (Canada)

Congestive Heart Failure Drugs Market Report Scope